Skip to main navigation
  Menu

ASLAN Pharmaceuticals

  • Pipeline
  • Our Team
  • Investor Relations
  • News & Publications
  • Contact
EN
english中文

Investor Relations

Investor Relations

  • Investor Home
  • Corporate Information
  • Stock Information
  • News & Events
  • Financial Information
    • SEC Filings
    • Quarterly Results
    • Analyst Coverage
  • Shareholder Services

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Alerts sign up

Required fields denoted by an asterisk ().
Alert type

SEC Filings

SEC Filings

SEC Filing Keyword Search

Filing date Form Description Filing Group View
Feb 25, 2021 6-K

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

Current Reports
View HTML
0001193125-21-055676.pdf
0001193125-21-055676.rtf
0001193125-21-055676.xls
Mar 01, 2021 6-K

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

Current Reports
View HTML
0001564590-21-009618.pdf
0001564590-21-009618.rtf
0001564590-21-009618.xls
Mar 01, 2021 6-K

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

Current Reports
View HTML
0001193125-21-063389.pdf
0001193125-21-063389.rtf
0001193125-21-063389.xls
Mar 01, 2021 424B5

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

Registration Statements
View HTML
0001193125-21-063788.pdf
0001193125-21-063788.rtf
0001193125-21-063788.xls
Mar 04, 2021 424B5

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

Registration Statements
View HTML
0001193125-21-068370.pdf
0001193125-21-068370.rtf
0001193125-21-068370.xls
Mar 04, 2021 6-K

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

Current Reports
View HTML
0001193125-21-068376.pdf
0001193125-21-068376.rtf
0001193125-21-068376.xls
Mar 18, 2021 6-K

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

Current Reports
View HTML
0001564590-21-014010.pdf
0001564590-21-014010.rtf
0001564590-21-014010.xls
Mar 26, 2021 F-3

Registration statement for certain foreign private issuers offered for certain transactions

Registration Statements
View HTML
0001193125-21-096567.pdf
0001193125-21-096567.rtf
0001193125-21-096567.xls
Mar 31, 2021 EFFECT

EFFECT

Other
View HTML
9999999995-21-001242.pdf
9999999995-21-001242.rtf
9999999995-21-001242.xls
Mar 31, 2021 UPLOAD

UPLOAD

Other
View HTML
0000000000-21-003845.pdf
0000000000-21-003845.rtf

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Current page 11
  • Page 12
  • Page 13
  • Page 14
  • Page 15
  • Next page Next ›
  • Last page Last »

Shareholder Tools

  • Print Page

    Print Page

  • RSS Feeds

    RSS Feeds

  • E-mail Alerts

    E-mail Alerts

Company

  • Pipeline
  • Our Team
  • Investor Relations
  • News & Publications
  • Contact
  • Terms and Conditions

Careers

For more information on employment opportunities at ASLAN, please contact us at careers@aslanpharma.com

Contact Us

Singapore Headquarters
83 Clemenceau Avenue
#12-03 UE Square
Singapore 239920
Tel: +65 6222 4235
Fax: +65 6225 2419

contact@aslanpharma.com